Clinical and health economic impact of isavuconazole for treatment of invasive aspergillosis and mucormycosis: a retrospective, matched multicentre cohort study in Germany
Our real-world analysis confirmed that first-line treatment initiated with isavuconazole resulted in clinical outcomes equivalent to those of L-AmB and/or voriconazole in patients with IA or IM. However, treatment costs during the in-patient stay were higher with isavuconazole.
Authors
- Karsten Spiekermann (ORCID: https://orcid.org/0000-0002-5139-4957)
- Beate Grüner (ORCID: https://orcid.org/0000-0001-6669-3741)
- Enrico Schalk (ORCID: https://orcid.org/0000-0003-1892-5098)
- Jörg Janne Vehreschild (ORCID: https://orcid.org/0000-0002-5446-7170)
- Johanna Kessel (ORCID: https://orcid.org/0000-0003-3246-5219)
- Sina M. Hopff (ORCID: https://orcid.org/0000-0002-8886-4596)
- Sabine Ehrlich
- Maria J. G. T. Vehreschild (ORCID: https://orcid.org/0000-0003-0446-3224)
- Martin Engelhard (ORCID: https://orcid.org/0000-0003-1921-9830)
- Sebastian Wingen‐Heimann (ORCID: https://orcid.org/0000-0002-4232-6944)
- Ben‐Niklas Baermann (ORCID: https://orcid.org/0009-0000-1699-9478)
Institutions
- Goethe University Frankfurt (DE)
- University of Cologne (DE)
- Düsseldorf University Hospital (DE)
- Integrated Oncology (United States) (US)
- German Center for Infection Research (DE)
- University Hospital Frankfurt (DE)
- Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (DE)
- University Hospital Cologne (DE)
- University Hospital Ulm (DE)
- Heinrich Heine University Düsseldorf (DE)
- Ludwig-Maximilians-Universität München (DE)
- Otto-von-Guericke-Universität Magdeburg (DE)
Publication Details
- Journal
- Infection
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1007/s15010-025-02674-x
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 0.00